Key Points
- Total revenue impressively rose by 20% to $8.4 billion.
- However, earnings per share decreased by 46% to $1.38.
- Non-GAAP EPS showed a slight decrease of under 1% to $4.97.
Amgen (AMGN 0.44%), the giant known for its innovative therapies, released its earnings for the second quarter of 2024 on Aug. 6. The company reported a significant increase in revenue, climbing 20% to $8.4 billion compared to Q2 2023, driven by its diverse portfolio and recent acquisition. However, GAAP earnings per share (EPS) fell by 46% from $2.57 to $1.38 due to higher operating expenses. Non-GAAP EPS showed a slight decline of under 1%, adjusting from $5.00 to $4.97. Overall, the quarter exhibited strong top-line growth but faced challenges in maintaining profitability due to increased costs.
| Metric | Q2 2024 | Q2 2023 | Change (YOY) |
|---|---|---|---|
| Total Revenue (in billions) | $8.39 | $6.99 | 20.1% |
| GAAP earnings per share | $1.38 | $2.57 | (46.3%) |
| Non-GAAP earnings per share | $4.97 | $5.00 | (0.6%) |
| GAAP operating income (in billions) | $1.91 | $2.69 | (28.9%) |
| Free cash flow (in billions) | $2.2 | $3.8 | (42.1%) |
| Source: Amgen |
Company Overview and Recent Focus
Amgen is a biopharmaceutical company well-regarded for its innovative medicines. Its key focuses recently include enhancing its product pipeline and integrating acquisitions efficiently. Success factors for Amgen involve strong product sales, effective cost management, and regulatory approvals for new treatments. The company's strategy is heavily anchored in developing and marketing novel therapies for various serious illnesses, including cancer and cardiovascular diseases.
Recently, Amgen has put significant effort into its research and development. This includes progressing with various clinical trials and acquiring Horizon Therapeutics to diversify its product offerings in the rare disease segment. Cost management has also been a pivotal activity due to rising operating expenses driven by acquisitions and increased R&D investments.
Quarterly Highlights
On the top line, the most notable achievement was a 20% rise in total revenue to $8.4 billion. This was driven by a robust 26% increase in product volume, counterbalanced by a 3% decrease in net selling prices. Excluding the sales from Horizon Therapeutics, product sales grew by 5%, primarily attributable to a 10% volume surge.
In terms of specific products, immunotherapy medication Repatha and osteoporosis treatment Prolia showed substantial growth, with sales increasing by 25% and 13%, respectively. Asthma treatment Tezepelumab saw sales rise by an impressive 76%. Additionally, the integration of Horizon Therapeutics contributed significantly, with Tepezza, Krystexxa, and Uplizna showing strong sales performance.
Despite the revenue growth, operating income faced challenges. GAAP operating income fell from $2.7 billion to $1.9 billion, while non-GAAP operating income rose from $3.5 billion to $3.9 billion. GAAP operating margins were squeezed, dropping by 16.5 percentage points to 23.7%, reflecting increased costs.
Total operating expenses surged by 51%, greatly affecting free cash flow, which declined from $3.8 billion in Q2 2023 to $2.2 billion this quarter. Increased R&D expenses and acquisitions were significant contributors to this rise.
Regulatory reviews and competition, particularly from biosimilars, remain significant challenges. Notably, the FDA issued a Complete Response Letter for Lumakras/Lumykras, delaying its new drug application. Despite these hurdles, Amgen's commitment to innovation remains strong, with numerous ongoing trials and expected product approvals.
Financial Outlook
Looking ahead, Amgen's management has revised its full-year guidance. Revenue expectations for 2024 have been tightened to a range of $32.8 billion to $33.8 billion, up slightly from the previous range. GAAP EPS guidance has been lowered to a range of $6.57 to $7.62, while non-GAAP EPS is now anticipated to be between $19.10 and $20.10.
Investors should keep an eye on Amgen’s ability to manage costs and navigate regulatory scrutiny in the upcoming quarters. Key points of attention include the outcomes of various clinical trials and regulatory decisions, especially for high-potential treatments like Tarlatamab and the further integration of Horizon Therapeutics' portfolio.
